Whither pathogenetic treatments for diabetic polyneuropathy?
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: Diabetic distal symmetric polyneuropathy (DSPN) occurs in around one‐third of patients with diabetes and is associated with significant morbidity and increased mortality. Diagnosis and clinical assessment of DSPN remain a challenge, not only for the physician in clinical practice but also for clinical trials. Optimal diabetes control is generally considered an essential first step in the prevention and management of DSPN. However, glycaemic control alone may be insufficient to prevent the development or progression of DSPN, especially in type 2 diabetes. Near‐normoglycaemia is also difficult to achieve in a significant proportion of patients. Although considerable advances have been made in symptomatic pain management, these have not addressed the problem of sensory deficits and have no impact on the underlying pathogenesis of DSPN. There remains a lack of treatment options that effectively target the natural history of the disease. Several pathogenetic treatment approaches have been investigated, but evidence from clinical trials is limited with a number of treatments having shown disappointing results. However, some pathogenetic therapies have shown clinically relevant improvements in neuropathic endpoints in randomised controlled trials, in particular α‐lipoic acid and Actovegin. These advances in DSPN disease modification need to be confirmed with further robust evidence from clinical trials together with a better understanding of the mechanisms of action of promising treatments. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690 · cited 2×
“In the absence of controlled trials, surgical nerve decompression cannot be recommended as a routine treatment option [7,24].”
BackgroundMethodSelf-citationYoung, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502
Self-citationAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868 · cited 1×
“Symptoms of pain have been reported to occur in 13–34% of patients with diabetes, with the risk of painful neuropathic symptoms considerably higher in type 2 diabetes than in type 1 diabetes [4,5].”
BackgroundSelf-citationYoung, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809 · cited 2×
“The recommended first-line treatment for painful DSPN is a tricyclic antidepressant, SNRI or an anticonvulsant, with priority given to consideration of comorbid conditions [6].”
BackgroundBoussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803 · cited 1×
“Meta-analysis of randomised controlled trials that reported neuropathy rate showed no significant reduction in occurrence with intensive versus standard therapy [16]; CI, confidence interval Pathogenetic Treatments for DSPN 329”
Tesfaye, S., Stevens, L. K., Stephenson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., Nuber, A., Pozza, G., & Ward, J. D. (1996) · Diabetologia · doi:10.1007/s001250050586 · Cited by 695
Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., & Mielck, A. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00555.x · Cited by 249 · cited 1×
“Symptoms of pain have been reported to occur in 13–34% of patients with diabetes, with the risk of painful neuropathic symptoms considerably higher in type 2 diabetes than in type 1 diabetes [4,5].”
BackgroundSelf-citationRandomized control trial of topical clonidine for treatment of painful diabetic neuropathy
Campbell, C. M., Kipnes, M. S., Stouch, B. C., Brady, K. L., Kelly, M., Schmidt, W. K., Petersen, K. L., Rowbotham, M. C., & Campbell, J. N. (2012) · Pain · doi:10.1016/j.pain.2012.04.014 · Cited by 165
Cited by
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Self-citationEpidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes
Hicks, C. W., & Selvin, E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1212-8 · Cited by 798
Selvarajah, D., Kar, D., Khunti, K., Davies, M. J., Scott, A. R., Walker, J., & Tesfaye, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30081-6 · Cited by 556
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes
Albers, J. W., & Pop-Busui, R. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0473-5 · Cited by 357
Petersen, E. A., Stauss, T. G., Scowcroft, J. A., Brooks, E. S., White, J. L., Sills, S. M., Amirdelfan, K., Guirguis, M. N., Xu, J., Yu, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0538 · Cited by 277
Understanding Diabetic Neuropathy: Focus on Oxidative Stress
Pang, L., Lian, X., Liu, H., Zhang, Y., Li, Q., Cai, Y., Ma, H., & Yu, X. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9524635 · Cited by 184
“However, its efficacy needs further investigation [145].”
Metadata
- Authors
- Boulton, A. J. M., Kempler, P., Ametov, A., & Ziegler, D.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2013-07
- Volume
- 29
- Issue
- 5
- Pages
- 327-333
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1899624445
- Cited by
- 89
- References
- 8
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.